According to International pharmaceutical company Galderma, almost 80% of adolescents and young adults aged 11 to 30 suffer from acne. To increase awareness of its topical acne treatment Differin, Galderma has awarded Primedia Unlimited’s X/procure a one-year advertising agreement. Differin (adapalene 0.1%) is a Topical Retinoid acne treatment with the advantage of being better tolerated.

The year-long advertising contract tasks X/procure to ensure that pharmacists are aware of the product and its benefits in the treatment of mild to moderate (non-inflammatory/comedonal and inflammatory) acne. X/procure‘s JD Henderson says, “Acne is an extremely common condition which unfortunately has a significant impact on the sufferer’s quality of life. Through the exposure of Differin on our system, we aim to assist in spreading the word to pharmacists nationwide that patients need not suffer, and that there is an effective treatment available.”

Devised by X/procure, the Intervention Ad, which is one of the chosen advertising mediums Galderma has authorised, elevates Differin against competing treatments in the same category. On this platform, advertising appears on screen when pharmacists order acne treatments. It reminds the pharmacist that Differin should be considered as the primary treatment for acne, and an essential part of maintenance therapy.

Created in 1981, Galderma is a joint venture between Nestlé and L'Oréal. It specialises in the research; development; and marketing of therapeutic; corrective; and aesthetic solutions for dermatology patients and is a leading player in the worldwide dermatology market.